LivaNova plc (LIVN) Tops Q3 EPS by 19c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
November 5, 2025 6:00 AM ESTDelivered double-digit reported and organic revenue growth and continued operating margin expansion
Raised full-year 2025 revenue, adjusted earnings per share, and adjusted free cash flow guidance(1)
Launched Essenz Perfusion System in China
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance.
Financial Summary and Highlights(1)
Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an organic... More